SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals (Nasdaq: HEPH - News) has retained Burrill LLC to provide exclusive strategic advisory services, with an initial focus on partnering Hollis-Eden’s lead program Apoptone, currently in Phase I/II development for hormone-refractory prostate cancer.
